A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Trial Profile

A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs ELND 005 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Transition Therapeutics
  • Most Recent Events

    • 31 Jul 2017 This trial has been completed in UK (on 2015-08-18) , according to European Clinical Trials Database.
    • 08 Jul 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 08 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top